{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 464390273
| IUPAC_name = (2''R'',3''R'')-3,5,7-trihydroxy-<br />2-[(2''R'',3''R'')-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)<br />-2,3-dihydrobenzo[''b''][1,4]dioxin-6-yl]chroman-4-one
| image = Silibinin skeletal.svg
| image2 = Silibinin 3D.png

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|silibinin}}
| routes_of_administration = [[Oral administration|Oral]] and [[Intravenous therapy|Intravenous]]

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 22888-70-6
| ATC_prefix = A05
| ATC_suffix = BA03
| PubChem = 31553
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 29263
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 9144
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 4RKY41TBTF
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08515
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 9509

<!--Chemical data-->
| C=25 | H=22 | O=10 
| molecular_weight = 482.44 g/mol
| smiles = O=C4c5c(O)cc(O)cc5O[C@H](c2ccc1O[C@@H]([C@H](Oc1c2)c3ccc(O)c(OC)c3)CO)[C@H]4O
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C25H22O10/c1-32-17-6-11(2-4-14(17)28)24-20(10-26)33-16-5-3-12(7-18(16)34-24)25-23(31)22(30)21-15(29)8-13(27)9-19(21)35-25/h2-9,20,23-29,31H,10H2,1H3/t20-,23+,24-,25-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = SEBFKMXJBCUCAI-HKTJVKLFSA-N
}}

'''Silibinin''' ([[International Nonproprietary Name|INN]]), also known as '''silybin '''(both from ''[[Silybum]]'', the [[Genus–differentia definition|generic]] name of the [[plant]] from which it is extracted), is the major active constituent of '''silymarin''', a standardized extract of the [[Silybum marianum|milk thistle]] seeds, containing a mixture of [[flavonolignan]]s consisting of silibinin, [[isosilibinin]], [[silicristin]], [[silidianin]], and others.  Silibinin itself is a mixture of two [[diastereomer]]s, silybin A and silybin B, in approximately equimolar ratio.<ref>{{cite journal | vauthors = Davis-Searles P, Nakanishi Y, Nam-Cheol K ''et al'' | year = 2005 | title = Milk Thistle and Prostate Cancer: Differential Effects of Pure Flavonolignans from Silybum marianum on Antiproliferative End Points in Human Prostate Carcinoma Cells | url = | journal = Cancer Research | volume = 65 | issue = 10| pages = 4448–57 | doi = 10.1158/0008-5472.CAN-04-4662 | pmid=15899838}}</ref>  The mixture exhibits a number of pharmacological effects, particularly in the liver, and there is some clinical evidence for the use of silibinin as a supportive element in alcoholic and child grade 'A' [[liver cirrhosis]].<ref name=Saller2008/>

==Pharmacology==
Poor water solubility and [[bioavailability]] of silymarin led to the development of enhanced formulations. '''Silipide''' (trade name '''Siliphos'''), a complex of silymarin and [[phosphatidylcholine]] (lecithin), is about 10 times more bioavailable than silymarin.<ref name=Kidd2005/> An earlier [http://www.phytosomes.info/public/siliphos.asp#references study] had concluded Siliphos to have 4.6 fold higher bioavailability.<ref>{{cite journal | vauthors = Barzaghi N, Crema F, Gatti G, Pifferi G, Perucca E | year = 1990 | title =  Pharmacokinetic studies on IdB 1016, a silybin- phosphatidylcholine complex, in healthy human subjects| pmid = 2088770| journal = Eur J Drug Metab Pharmacokinet | volume = 15 | issue = | pages = 333–8 | doi=10.1007/bf03190223}}</ref>  It has been also reported that silymarin inclusion complex with β-[[cyclodextrin]] is much more soluble than silymarin itself.<ref name=Voinovich2009/> There have also been prepared [[glycoside]]s of silybin, which show better water solubility and even stronger hepatoprotective effect.<ref name=Kosina2002/>

Silymarin, as other [[flavonoid]]s, has been shown to inhibit [[P-glycoprotein]]-mediated cellular efflux.<ref name=Zhou2004/> The modulation of P-glycoprotein activity may result in altered absorption and bioavailability of drugs that are P-glycoprotein substrates. It has been reported that silymarin inhibits [[cytochrome P450]] enzymes and an interaction with drugs primarily cleared by P450s cannot be excluded.<ref name=Wu2009/>

== Toxicity ==
A [[phase I clinical trial]] in humans with prostate cancer designed to study the effects of high dose silibinin found 13 grams daily to be well tolerated in patients with advanced prostate cancer with asymptomatic liver toxicity ([[hyperbilirubinemia]] and elevation of [[alanine aminotransferase]]) being the most commonly seen adverse event.<ref>{{cite journal | journal = Investigational New Drugs | year = 2007 | volume = 25 | issue = 2 | pages = 139–146 | title = A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients |author1=Thomas W. Flaig |author2=Daniel L. Gustafson |author3=Lih-Jen Su |author4=Joseph A. Zirrolli |author5=Frances Crighton |author6=Gail S. Harrison |author7=A. Scott Pierson |author8=Rajesh Agarwal |author9=L. Michael Glodé | doi=10.1007/s10637-006-9019-2}}</ref>

Silymarin is also devoid of embryotoxic potential in animal models.<ref name=Fraschini2002/><ref name=Hahn1968/>

== Medical uses ==
{{main article|Silybum marianum#Research}}
Silibinin is available as drug (Legalon SIL (Madaus) (D, CH, A) and Silimarit (Bionorica), a Silymarin product) in some EU countries and used in the treatment of toxic liver damage (e.g. IV treatment in case of [[Amanita phalloides|death cap]] poisoning); as adjunctive therapy in chronic hepatitis and cirrhosis.

For approved drug preparations and parenteral applications in the treatment of ''Amanita'' mushroom poisoning, the water-soluble silibinin-C-2’,3-dihyrogensuccinate disodium salt is used. In 2011,  the same compound also received Orphan Medicinal Product Designation for the prevention of recurrent hepatitis C in liver transplant recipients by the European Commission.<ref>Rottapharm|Madaus. [http://www.rotta.com/en/service/media/comunicatiStampa/pdf/legalon_ENG.pdf Media Communications Legalon®]. Retrieved March 6 2017.</ref>

== Potential medical uses ==
Silibinin is under investigation to see whether it may have a role in cancer treatment (e.g. due to its inhibition of [[STAT3]] signalling).<ref>{{cite journal |vauthors=Bosch-Barrera J, Menendez JA |title=Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy |journal=Cancer Treat. Rev. |volume=41 |issue=6 |pages=540–6 |year=2015 |pmid=25944486 |doi=10.1016/j.ctrv.2015.04.008 |type=Review}}</ref>

Silibinin also has a number of potential mechanisms that could benefit the skin. These include chemoprotective effects from environmental toxins, anti-inflammatory effects, protection from UV induced photocarcinogenesis, protection from sunburn, protection from [[Ultraviolet|UVB]]-induced [[epidermal hyperplasia]], and [[DNA repair]] for UV induced DNA damage (double strand breaks).<ref>{{cite journal|last1=Singh|first1=Rana P.|last2=Agarwal|first2=Rajesh|title=Cosmeceuticals and silibinin|journal=Clinics in Dermatology|date=September 2009|volume=27|issue=5|pages=479–484|doi=10.1016/j.clindermatol.2009.05.012|pmid=19695480|pmc=2767273}}</ref>

== Biotechnology ==
Silymarin can be produced in [[callus (cell biology)|callus]] and cells suspensions of ''[[Silybum marianum]]'' and substituted [[pyrazinecarboxamide]]s can be used as abiotic [[elicitor]]s of flavolignan production.<ref>{{cite journal | vauthors = Tůmová L, Tůma J, Megušar K, Doleža M | year = 2010 | title = Substituted Pyrazinecarboxamides as Abiotic Elicitors of Flavolignan Production in Silybum marianum (L.) Gaertn Cultures in Vitro | url = | journal = Molecules | volume = 15 | issue = 1| pages = 331–340 | doi = 10.3390/molecules15010331 }}</ref>

== References ==
{{Reflist|30em|refs=

<ref name=Kidd2005>{{cite journal |vauthors=Kidd P, Head K |title=A review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos) |journal=Alternative Medicine Review |volume=10 |issue=3 |pages=193–203 |year=2005 |pmid=16164374 |doi= |url=http://www.thorne.com/altmedrev/.fulltext/10/3/193.pdf |accessdate=2010-12-14}}</ref>

<ref name=Kosina2002>{{cite journal |vauthors=Kosina P, Kren V, Gebhardt R, Grambal F, Ulrichová J, Walterová D |title=Antioxidant properties of silybin glycosides |journal=Phytotherapy Research : PTR |volume=16 Suppl 1 |issue= |pages=S33–9 |year=2002  |pmid=11933137 |doi= 10.1002/ptr.796}}</ref>

<ref name=Saller2008>{{cite journal |vauthors=Saller R, Brignoli R, Melzer J, Meier R |title=An updated systematic review with meta-analysis for the clinical evidence of silymarin |journal=Forschende Komplementärmedizin |volume=15 |issue=1 |pages=9–20 |year=2008 |pmid=18334810 |doi=10.1159/000113648 |url=http://content.karger.com/produktedb/produkte.asp?typ=fulltext&file=000113648 |accessdate=2010-12-14}}</ref>

<ref name=Voinovich2009>{{cite journal |vauthors=Voinovich D, Perissutti B, Grassi M, Passerini N, Bigotto A |title=Solid state mechanochemical activation of ''Silybum marianum'' dry extract with betacyclodextrins: Characterization and bioavailability of the coground systems |journal=Journal of Pharmaceutical Sciences |volume=98 |issue=11 |pages=4119–29 |year=2009 |pmid=19226635 |doi=10.1002/jps.21704}}</ref>

<ref name=Wu2009>{{cite journal |vauthors=Wu JW, Lin LC, Tsai TH |title=Drug-drug interactions of silymarin on the perspective of pharmacokinetics |journal=Journal of Ethnopharmacology |volume=121 |issue=2 |pages=185–93 |year=2009 |pmid=19041708 |doi=10.1016/j.jep.2008.10.036 |url=http://linkinghub.elsevier.com/retrieve/pii/S0378-8741(08)00621-1 |accessdate=2010-12-14}}</ref>

<ref name=Zhou2004>{{cite journal |vauthors=Zhou S, Lim LY, Chowbay B |title=Herbal modulation of P-glycoprotein |journal=Drug Metabolism Reviews |volume=36 |issue=1 |pages=57–104 |year=2004 |pmid=15072439 |doi=10.1081/DMR-120028427 |url=http://www.informapharmascience.com/doi/abs/10.1081/DMR-120028427 }}</ref>

<ref name=Fraschini2002>{{cite journal |vauthors=Fraschini F, Demartini G, Esposti D |title=Pharmacology of Silymarin |journal=Clinical Drug Investigation |volume=22 |issue=1 |pages=51–65 |year=2002 |doi=10.2165/00044011-200222010-00007 | url=http://adisonline.com/druginvestigation/Abstract/2002/22010/Pharmacology_of_Silymarin.7.aspx }}</ref>

<ref name=Hahn1968>{{cite journal |vauthors=Hahn G, Lehmann HD, Kürten M, Uebel H, Vogel G |title=On the pharmacology and toxicology of silymarin, an antihepatotoxic active principle from Silybum marianum (L.) gaertn |journal=Arzneimittelforschung |volume=18 |issue=6 |pages=698–704 |year=1968 |pmid=5755807 }}</ref>

}}

== External links ==
* [http://www.mayoclinic.com/health/silymarin/NS_patient-milkthistle Review of the Quality of Evidence for Milk Thistle Use from MayoClinic.com]
*{{cite journal |vauthors=Morazzoni P, Bombardelli E |title=''Silybum marianum'' (cardus marianus) |journal=Fitoterapia |volume=66 |pages=3–42 |year=1994}}
*{{cite journal |vauthors=Saller R, Meier R, Brignoli R |title=The use of silymarin in the treatment of liver diseases |journal=Drugs |volume=61 |issue=14 |pages=2035–63 |year=2001 |pmid=11735632 |doi=10.2165/00003495-200161140-00003 }}
* {{MeshName|Silymarin}}

{{Bile and liver therapy}}
{{lignan}}

[[Category:Antidotes]]
[[Category:Flavonolignans]]
[[Category:Phenols]]